Short answer
Relay Therapeutics, Inc. (RLAY) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $350,000 (down 48.2% year over year) with net income of −$84M.
Q2 2026 key financials · XBRL
- Revenue
- $350,000
- −48.2% YoY · −88.3% QoQ
- Net income
- −$84M
- −18.9% YoY · −14.2% QoQ
- Operating margin
- -25949.7%
- EPS (diluted)
- −$0.41
- +0.0% YoY · +0.0% QoQ
Source: XBRL data from the Relay Therapeutics, Inc. (RLAY) Q2 2026 10-Q on SEC EDGAR. USD.
Relay Therapeutics, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New combination-therapy exposure: April 2026 Pfizer supply agreement depends on regulatory feedback for planned Phase 3 zovegalisib trial
- Regulatory risk: FDA may require a companion diagnostic for zovegalisib in a biomarker-defined population
- Clinical-development risk: No large-scale pivotal trial successfully completed
- Operational risk: Pfizer supply of atirmociclib and palbociclib supports planned Phase 3 combination trial
- Enrollment risk: Competitor trials and narrow biomarker eligibility may slow patient recruitment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Relay Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.